Testing and Interpreting the “Right” Hypothesis—Comment on “Non-proportional Hazards — An Evaluation of the MaxCombo Test in Cancer Clinical Trials”

References

• Aalen, O. O., Cook, R. J., and Røysland, K. (2015), “Does Cox Analysis of a Randomized Survival Study Yield a Causal Treatment Effect?” Lifetime Data Analysis, 21, 579–593. DOI: 10.1007/s10985-015-9335-y.
   PubMed Web of Science ®Google Scholar
• Bartlett, J. W., Morris, T. P., Stensrud, M. J., Daniel, R. M., Vansteelandt, S. K., and Burman, C.-F. (2020), “The Hazards of Period Specific and Weighted Hazard Ratios,” Statistics in Biopharmaceutical Research, 12, 518–519. DOI: 10.1080/19466315.2020.1755722.
   PubMed Web of Science ®Google Scholar
• Bauer, P., and Posch, M. (2004), “Modification of the Sample Size and the Schedule of Interim Analyses in Survival Trials based on Data Inspections, by H. Schäfer and H.-H. Müller, Statistics in Medicine 2001; 20: 3741–3751,” Statistics in Medicine, 23, 1333–1335. DOI: 10.1002/sim.1759.
   PubMed Web of Science ®Google Scholar
• Bretz, F., Maurer, W., Brannath, W., and Posch, M. (2009), “A Graphical Approach to Sequentially Rejective Multiple Test Procedures,” Statistics in Medicine, 28, 586–604. DOI: 10.1002/sim.3495.
   PubMed Web of Science ®Google Scholar
• Freidlin, B., and Korn, E. L. (2019), “Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?,” Journal of Clinical Oncology, 37, 3455–3459. DOI: 10.1200/JCO.19.01681.
   PubMed Web of Science ®Google Scholar
• Ghosh, P., Ristl, R., König, F., Posch, M., Jennison, C., Götte, H., Schüler, A., and Mehta, C. (2022), “Robust Group Sequential Designs for Trials with Survival Endpoints and Delayed Response,” Biometrical Journal, 64, 343–360. DOI: 10.1002/bimj.202000169.
   PubMed Web of Science ®Google Scholar
• Jörgens, S., Wassmer, G., König, F., and Posch, M. (2019), “Nested Combination Tests with a Time-to-Event Endpoint using a Short-Term Endpoint for Design Adaptations,” Pharmaceutical Statistics, 18, 329–350. DOI: 10.1002/pst.1926.
   PubMed Web of Science ®Google Scholar
• Klinglmueller, F., Posch, M., and Koenig, F. (2014), “Adaptive Graph-based Multiple Testing Procedures,” Pharmaceutical Statistics, 13, 345–356. DOI: 10.1002/pst.1640.
   PubMed Web of Science ®Google Scholar
• Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., Leon, L. F., Liao, J. J., Liu, R., Luo, X., Mukhopadhyay, P., Qin, R., Tatsuoka, K., Wang, X., Wang, Y., Zhu, j., Chen, T. T., Iacona, R., and Cross-Pharma Non-proportional Hazards Working Group. (2020), “Alternative Analysis Methods for Time to Event Endpoints under Nonproportional Hazards: A Comparative Analysis,” Statistics in Biopharmaceutical Research, 12, 187–198. DOI: 10.1080/19466315.2019.1697738.
   Web of Science ®Google Scholar
• Magirr, D., and Burman, C.-F. (2019), “Modestly Weighted Logrank Tests,” Statistics in Medicine, 38, 3782–3790. DOI: 10.1002/sim.8186.
   PubMed Web of Science ®Google Scholar
• Magirr, D., and Burman, C.-F. (2021), “The Strong Null Hypothesis and the Maxcombo Test: Comment on “Robust Design and Analysis of Clinical Trials with Nonproportional Hazards: A Straw Man Guidance form a Cross-pharma Working Group,” Statistics in Biopharmaceutical Research, 1–2, 2021. DOI: 10.1080/19466315.2021.1917451.
   Web of Science ®Google Scholar
• Magirr, D., Jaki, T., Koenig, F., and Posch, M. (2016), “Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials,” PloS One, 11, e0146465. DOI: 10.1371/journal.pone.0146465.
   PubMed Web of Science ®Google Scholar
• Ristl, R., Ballarini, N. M., Götte, H., Schüler, A., Posch, M., and König, F. (2021a), “Delayed Treatment Effects, Treatment Switching and Heterogeneous Patient Populations: How to Design and Analyze RCTS in Oncology,” Pharmaceutical Statistics, 20, 129–145. DOI: 10.1002/pst.2062.
   PubMed Web of Science ®Google Scholar
• Ristl, R., Götte, H., Schüler, A., König, F., and Posch, M. (2021b), “Testing Procedures for the Comparison of Multiple Characteristics of Different Survival Functions,” in Paper presented at the Annual Meeting of the Austrian Swiss Region at the International Biometric Society.
   Google Scholar
• Roychoudhury, S., Anderson, K. M., Ye, J., and Mukhopadhyay, P. (2021), “Robust Design and Analysis of Clinical Trials with Nonproportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group,” Statistics in Biopharmaceutical Research, 1–15. DOI: 10.1080/19466315.2021.1874507.
   Web of Science ®Google Scholar
• Shafrin, J., Schwartz, T. T., Okoro, T., and Romley, J. A. (2017), “Patient versus Physician Valuation of Durable Survival Gains: Implications for Value Framework Assessments,” Value in Health, 20, 217–223. DOI: 10.1016/j.jval.2016.11.028.
   PubMed Web of Science ®Google Scholar
• Shen, Y.-L., Wang, X., Sirisha, M., Mulkey, F., Zhou, J., Gao, X., Zhang, L., Gwise, T., Tang, S., Theoret, M., Pazdur, R., and Sridhara, R. (2022) “Nonproportional Hazards—An Evaluation of the MaxCombo Test in Cancer Clinical Trials,” Statistics in Biopharmaceutical Research. DOI: 10.1080/19466315.2021.2008485..
   Web of Science ®Google Scholar